LON:STX Shield Therapeutics (STX) Share Price, News & Analysis GBX 7.60 -0.25 (-3.18%) As of 10/17/2025 12:23 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesBuy This Stock About Shield Therapeutics Stock (LON:STX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Shield Therapeutics alerts:Sign Up Key Stats Today's Range 7.40▼ 850-Day Range 4.54▼ 952-Week Range 2.10▼ 9.10Volume1.28 million shsAverage Volume2.75 million shsMarket Capitalization£80.70 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 15Consensus RatingBuy Company Overview Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru® is commercialized in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer®/ Feraccru® in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada. Accrufer®/Feraccru® has patent coverage until the mid-2030s. Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics. Read More Shield Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreSTX MarketRank™: Shield Therapeutics scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingShield Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialShield Therapeutics has a consensus price target of GBX 15, representing about 97.4% upside from its current price of GBX 7.60.Amount of Analyst CoverageShield Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Shield Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Shield Therapeutics is -380.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Shield Therapeutics is -380.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioShield Therapeutics has a P/B Ratio of 138.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for STX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldShield Therapeutics does not currently pay a dividend.Dividend GrowthShield Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for STX. News and Social Media1.1 / 5News SentimentN/A Search Interest118 people have searched for STX on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.MarketBeat Follows2 people have added Shield Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Shield Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.04% of the stock of Shield Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 6.66% of the stock of Shield Therapeutics is held by institutions.Read more about Shield Therapeutics' insider trading history. Receive STX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STX Stock News HeadlinesShield Therapeutics (LON:STX) jumps 22% this week, taking one-year gains to 110%October 7, 2025 | finance.yahoo.comShield Therapeutics Reports Positive Results for Ferric Maltol in Heart Failure PatientsAugust 27, 2025 | msn.comClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enforcing that means a $5.39 billion pot must be paid out to everyday Americans. See, virtually every AI model is built off stolen data...October 19 at 2:00 AM | Angel Publishing (Ad)Shield Therapeutics First Half 2025 Earnings: US$0.009 loss per share (vs US$0.02 loss in 1H 2024)August 24, 2025 | finance.yahoo.comThis 5p penny stock is crushing the stock market in 2025August 18, 2025 | msn.comShield Therapeutics revenue jumps on rising Accrufer prescriptionsJuly 24, 2025 | lse.co.ukShield Therapeutics plc's (LON:STX) Path To ProfitabilityJuly 16, 2025 | finance.yahoo.comShield Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagApril 26, 2025 | uk.finance.yahoo.comSee More Headlines STX Stock Analysis - Frequently Asked Questions How have STX shares performed this year? Shield Therapeutics' stock was trading at GBX 2.70 at the beginning of 2025. Since then, STX stock has increased by 181.5% and is now trading at GBX 7.60. How were Shield Therapeutics' earnings last quarter? Shield Therapeutics plc (LON:STX) posted its quarterly earnings results on Thursday, April, 24th. The company reported ($3.00) EPS for the quarter. Shield Therapeutics had a negative trailing twelve-month return on equity of 470.50% and a negative net margin of 173.43%. How do I buy shares of Shield Therapeutics? Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Shield Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), AstraZeneca (AZN), Model N (MODN), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS) and Cellectis (CLLS). Company Calendar Last Earnings4/24/2025Today10/19/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryComputer Hardware Current SymbolLON:STX CIKN/A Webwww.shieldtherapeutics.com Phone+44-191-5118500FaxN/AEmployees40,000Year FoundedN/APrice Target and Rating Average Price Target for Shield TherapeuticsGBX 15 High Price TargetGBX 15 Low Price TargetGBX 15 Potential Upside/Downside+97.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)GBX (0.02) Trailing P/E RatioN/A Forward P/E Ratio107.40 P/E GrowthN/ANet Income-£36.28 million Net Margins-173.43% Pretax MarginN/A Return on Equity-470.50% Return on Assets-47.85% Debt Debt-to-Equity Ratio3,691.50 Current Ratio1.05 Quick Ratio2.16 Sales & Book Value Annual Sales£41.50 million Price / Sales1.94 Cash FlowGBX 1.19 per share Price / Cash Flow6.36 Book ValueGBX 0.05 per share Price / Book138.88Miscellaneous Outstanding Shares1,061,803,000Free FloatN/AMarket Cap£80.70 million OptionableNot Optionable Beta1.42 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (LON:STX) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shield Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Shield Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.